Patents by Inventor Maria Arico

Maria Arico has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120148615
    Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.
    Type: Application
    Filed: January 24, 2012
    Publication date: June 14, 2012
    Inventors: Vega MASIGNANI, Beatrice Maria Arico
  • Patent number: 8124098
    Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: February 28, 2012
    Assignee: Novartis Vaccines and Diagnostics SRL
    Inventors: Vega Masignani, Beatrice Maria Arico
  • Publication number: 20110076300
    Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.
    Type: Application
    Filed: August 27, 2010
    Publication date: March 31, 2011
    Inventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
  • Publication number: 20110020390
    Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.
    Type: Application
    Filed: February 20, 2009
    Publication date: January 27, 2011
    Inventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
  • Publication number: 20100303822
    Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.
    Type: Application
    Filed: May 25, 2010
    Publication date: December 2, 2010
    Inventors: Vega Masignani, Beatrice Maria Aricò
  • Publication number: 20100221256
    Abstract: NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion can be modulated by targeting these three proteins. NadA allelic variants are disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in E. coli. Mature App proteins are disclosed. Knockout mutants are disclosed. Vesicles from non-Neisserial hosts with heterologous adhesin expression are disclosed.
    Type: Application
    Filed: May 6, 2010
    Publication date: September 2, 2010
    Inventors: Maria Arico, Maurizio Comanducci
  • Patent number: 7749518
    Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: July 6, 2010
    Assignee: Novartis Vaccines and Diagnostics SRL
    Inventors: Vega Masignani, Beatrice Maria Arico
  • Publication number: 20080267966
    Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.
    Type: Application
    Filed: May 16, 2005
    Publication date: October 30, 2008
    Inventors: Vega Masignani, Beatrice Maria Arico
  • Publication number: 20080193971
    Abstract: Meningococcal antigens are cleaved by human lactoferrin. The invention is based on the identification of the cleavage products of this reaction, and provides a method for cleaving a neisserial polypeptide, comprising the step of mixing the polypeptide with a lactoferrin enzyme. The invention also provides polypeptides obtainable by this process (i.e. the cleavage products of the lactoferrin digestion) which might be useful in the preparation of anti-meningococcal vaccines. Proteins of particular interest are meningococcal proteins 287 and App.
    Type: Application
    Filed: April 28, 2005
    Publication date: August 14, 2008
    Inventors: Davide Serruto, Maria Arico
  • Publication number: 20060051840
    Abstract: Two or more Neisserial proteins (e.g. A and B) are expressed as a single hybrid protein which can be represented simply by the formula NH2-A-B—COOH.
    Type: Application
    Filed: February 25, 2005
    Publication date: March 9, 2006
    Applicant: Chiron Srl
    Inventors: Maria Arico, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marizia Guiliani, Mariagrazia Pizza
  • Publication number: 20050232936
    Abstract: NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion can be modulated by targeting these three proteins. NadA allelic variants are disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in E. coli. Mature App proteins are disclosed. Knockout mutants are disclosed. Vesicles from non-Neisserial hosts with heterologous adhesin expression are disclosed.
    Type: Application
    Filed: July 26, 2002
    Publication date: October 20, 2005
    Applicant: CHIRON CORPORATION
    Inventors: Maria Arico, Maurizio Comanducci